January 25th 2024
The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Targeted Therapies for the Management of Eosinophilic Esophagitis Across the Life Cycle: The Role of the Pharmacist in Patient Identification and Optimization, featuring a Pat...
1.5 Credits / Immunology
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
Dr David Pariser Highlights Comorbidities and Treatments in the Pipeline for Atopic Dermatitis
December 10th 2020The comorbidities associated with atopic dermatitis can be substantial, and the disease can have a significant burden on quality of life, but new biologics and other future treatments may help, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.
Watch
Dr David Pariser Discusses the Significant Burden of Atopic Dermatitis
December 5th 2020The financial, physical, and social burdens of atopic dermatitis can be substantial, especially for patients who had the condition as children into adulthood, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.
Watch
Behavior Intervention Can Increase Physical Activity and Improve Asthma Control
November 25th 2020Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.
Read More
Dr Nicola Hanania: Treatment of T2-High Asthma Is Constantly Evolving
November 11th 2020Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.
Watch
Overuse of Reliever Inhalers Does Not Necessarily Mean Greater Health Care Utilization
November 8th 2020Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.
Read More
Dr Anne Reihman: Anti–IL-5 Therapies Can Be Life-Changing for Patients With Eosinophilic Asthma
November 7th 2020Categorizing by eosinophilic/noneosinophilic subtype enables better targeted treatment, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.
Watch
Weighing the Pros, Cons of At-Home Use of Biologics for Asthma
October 28th 2020When the first biologic to treat asthma was approved by the FDA in 2003, it needed to be administered subcutaneously in the physician’s office. Now, there are 3 options available for at-home use: mepolizumab, benralizumab, and dupilumab.
Read More
Addressing the QOL Impact and Disease Burden on the Families of Adolescents With Atopic Dermatitis
October 19th 2020Atopic dermatitis (AD) has a negative impact on quality of life, and the burden of this disease in adolescents and their parents should be taken into account as part of the management of AD.
Read More
Dr J. Allen Meadows on Making the Decision to Put a Patient With Asthma on a Biologic
October 14th 2020Patients with severe asthma are good candidates for biologics, but choosing which biologic requires a shared decision-making conversation, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.
Watch
Dr J. Allen Meadows Outlines New Long-term Safety, Efficacy Data for Dupilumab in Asthma
October 10th 2020New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.
Watch
Dupilumab Improves Lung Function, Reduces Asthma Flares in Patients on High-Dose ICS
October 9th 2020Patients with type 2-high asthma who were being treated with high-dose inhaled corticosteroids (ICS) had reduced exacerbations and improved lung function when they were switched to dupilumab.
Read More
Dr Neal Jain on the Real-World Results of Dupilumab in Asthma
September 26th 2020In the real world, dupilumab has been as effective as the results in clinical trials, and patients are seeing low exacerbation rates, emergency department visits, and hospitalizations, explained Neal Jain, MD, FAAP, FAAAAI.
Watch
Pediatric Asthma Health Care Utilization Following Onset of COVID-19 Pandemic
September 25th 2020Following the onset of the coronavirus disease 2019 (COVID-19) pandemic, changes in pediatric asthma health care delivery patterns resulted in reduced hospital admissions and systemic steroid prescriptions in Philadelphia.
Read More
Dr Neal Jain Discusses the Use of Dupilumab in Oral Steroid–Dependent Asthma
September 19th 2020Patients who have oral corticosteroid–dependent asthma are recommended to use dupilumab, which reduces the use of oral steroids, explained Neal Jain, MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research.
Watch
Real-World Study: Dupilumab for Atopic Dermatitis More Effective Than Clinical Trial Results
September 12th 2020The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.
Read More
Dr Neal Jain Explains How Dupilumab Differentiated Itself as a Late Entrant to the Asthma Market
September 11th 2020Even though dupilumab was a late entrant to the market to treat asthma, its efficacy “speaks for itself,” said Neal Jain MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research, Arcadia Allergy & Asthma, and San Tan Allergy & Asthma.
Watch
AI Smartphone App Could Improve Diagnosis of Psoriasis, Atopic Dermatitis, Eczema
June 23rd 2020Inflammatory skin diseases are often diagnosed by "first impression" and can be easily misdiagnosed. A new smartphone app using artificial intelligence (AI) may be able to assist with the diagnosis of psoriasis, atopic dermatitis, and eczema.
Read More